EXAS — Exact Sciences Balance Sheet
0.000.00%
- $20.03bn
- $21.40bn
- $3.25bn
Annual balance sheet for Exact Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,030 | 632 | 778 | 1,038 | 965 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 217 | 158 | 204 | 249 | 299 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1,426 | 982 | 1,194 | 1,571 | 1,556 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 773 | 862 | 853 | 830 | 842 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 6,685 | 6,227 | 6,471 | 5,928 | 5,861 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 517 | 413 | 515 | 732 | 641 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3,297 | 3,184 | 3,326 | 3,526 | 3,460 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 3,388 | 3,043 | 3,145 | 2,402 | 2,401 |
| Total Liabilities & Shareholders' Equity | 6,685 | 6,227 | 6,471 | 5,928 | 5,861 |
| Total Common Shares Outstanding |